Results 131 to 140 of about 28,392 (204)

A Narrative Review of Augmentation Strategies in Obsessive-Compulsive Disorder: Antipsychotics as Mainstay and Emerging Role of Extended-Release Methylphenidate. [PDF]

Pharmaceuticals (Basel)
Grigaitytė J, Strumila R.
europepmc   +1 more source

Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial. [PDF]

Drug Des Devel Ther
Dong F, Wang Z, Li C, Li X, Zhu D, Li J, Wang Z, Gong J, Zhou J, Liu H, Zhang Y, Zhang X, Chen X, Yu M, Tan X, Qian M, Luo Y, Guo WJ, Xie S, Huang J, Zhao J, Wan J, Shan Y, Li N, Wang J, Ju Y, Wang J, Bian Q, Wang G.   +28 more
europepmc   +1 more source

Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer's Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis. [PDF]

CNS Drugs
Jiang C, Krivinko J, Yu Z, Sweet RA, Zeng L, Wang H, Ding Y, Zeng Z, Kofler J, Wang L.   +9 more
europepmc   +1 more source

Case Report: Early onset pulmonary embolism following antipsychotic polypharmacy in an acute psychiatric setting. [PDF]

Front Psychiatry
Fesenmeier S, Aigner M, Filipovits D, Höflich A.   +3 more
europepmc   +1 more source

GLUT5-Driven Gut-Liver Axis Injury Mediating Olanzapine-Induced NAFLD and Dapagliflozin Intervention. [PDF]

Drug Des Devel Ther
Chen X, Zhang Y, Wang J, Chen L, He SM, Wang DD.   +5 more
europepmc   +1 more source

Neuropsychiatric-pharmacologic synergy: interaction between psychiatric polypharmacy and cancer treatment-related neurotoxicity. [PDF]

Oxf Med Case Reports
Woytowitz SP, Manchee C.
europepmc   +1 more source

Real-world antipsychotic prescribing pathways and treatment modifications in schizophrenia spectrum disorders: evidence from the United Arab Emirates. [PDF]

Front Pharmacol
Bokhari SA, Elnoor M, Javaid SF, Alnor MA.   +3 more
europepmc   +1 more source

Interventions to prevent antipsychotic-induced weight gain and metabolic complications in individuals with a first-episode psychosis and minimal antipsychotic exposure: a systematic review and meta-analysis. [PDF]

Psychol Med
O'Mahony BW, Burke T, Hamill R, Gannon L, Perry BI, Siskind D, Pawełczyk T, O'Shea D, O'Donoghue B.   +8 more
europepmc   +1 more source

QT-related adverse events with ondansetron and olanzapine: a real-world FAERS analysis with implications for oncology anti-emetic practice. [PDF]

Front Pharmacol
Gandhi A, Parhizgar A, Bhise V.
europepmc   +1 more source